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Abstract 
 
Background  Clostridium difficile infection (CDI) is the most frequent cause of hospital-acquired 
infectious diarrhea in developed countries.  Approximately 19-20% of affected patients will 
experience a symptomatic recurrence following their first episode of Clostridium difficile-
associated diarrhea (CDAD).  Risk factors for the initial CDAD episode have been well-
documented, however, epidemiologic risk factors for recurrent CDAD have not been described 
in as much detail.  It is hypothesized that initial treatment could be a risk factor for recurrent 
CDAD.  The CT Emerging Infections Program  (EIP) conducts laboratory-based surveillance for 
CDAD in New Haven County,  however, routine surveillance does not collect treatment data.  
Therefore, we conducted a pilot case-control study on CDAD patients at Yale New Haven 
Hospital (YNHH) during the years 2010-2011 to examine initial CDAD treatment as a risk factor 
for recurrent CDAD. 
Methods  Cases and control patients were identified from CT EIP CDI surveillance data.  A 
patient with recurrent CDAD is defined as having had another positive C. difficile stool specimen 
between two to eight weeks after the last positive C. difficile stool specimen.  Both cases and 
controls were persons hospitalized at YNHH in 2010-2011; cases had recurrent disease, controls 
had only a single (incident-only) episode of CDAD. Cases and controls were matched within +/- 
two years of age. Medical charts of cases and controls were reviewed to collect treatment 
information related to the incident CDAD episode and severity of the incident case of CDAD, as 
defined by the Society for Healthcare Epidemiologists of America.  Cases and controls were 
compared on categorical variables with the Fisher’s Exact Test or the chi-squared test. 
Differences in continuous variables were analyzed with the Student’s t test.  Stratified analyses 
were conducted by severity of incident infection and sex, using the Mantel-Haenszel chi-squared 
test.   
Results Eighty-one persons with recurrent CDAD were eligible cases, matched to 122 controls 
with incident-only CDAD.  Persons starting on vancomycin as compared to metronidazole were 
found to have a lower risk of recurrence, regardless of initial disease severity.  Persons treated 
with a course of vancomycin <10 days had a higher risk of recurrence than those treated longer.  
Initial treatment with vancomycin appeared to substantially reduce the risk of recurrence: 
recurrent cases were less likely to have received initial vancomycin therapy (odds ratio [OR]: 
0.59; 95% confidence interval [CI]: 0.20, 1.76) and received shorter courses of vancomycin (OR: 
2.11; 95% CI: 0.57, 7.82) than controls.   
Conclusions  Persons started on vancomycin as compared to metronidazole have a lower risk of 
recurrence, regardless of initial CDI severity.  Vancomycin is being underused at YNHH to 
initially treat severe CDAD.  Our sample size was too small to demonstrate statistically 
significant differences between recurrent and control cases, but in light of these point estimates, 
YNHH may want to revisit their established clinical practices for treatment of CDAD.  Ongoing 
surveillance for CDAD and recurrent CDAD may also want to include initial treatment 
information. 
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Introduction 
Clostridium difficile is a gram-positive, cytotoxin-producing anaerobic bacterium first 
identified in 1935 from the stool of healthy newborn infants1.  It was not shown to be a cause of 
diarrhea until the late 1970s2.  Following its recognition as a pathogen, it was found to be a 
normal part of gut flora in up to 3% of healthy adults and in 24% of hospitalized patients3.  
Today, Clostridium difficile infection (CDI) is the most frequent cause of hospital-acquired 
infectious diarrhea in developed countries4, and also accounts for 20-30% of antibiotic-
associated diarrhea5,6. The case fatality rate in the US is 10.1% overall and 15.4% in those over 
70 years of age7. Costs for care of individual cases of Clostridium difficile-associated diarrhea 
(CDAD)  ranges from $3006 per case8 to as high as $15,3979, with the annual cost of hospital 
care for patients with CDAD in the United States ranging from $1 billion10 up to as much as $4.8 
billion11.   
This spore-forming bacillus produces two toxins, toxin A and toxin B, which are 
pathogenic to intestinal epithelial cells and mediate the resulting disease12.  Growing evidence 
suggests the emergence of a hypervirulent, epidemic strain as an important factor in the recent 
increases in incidence and severity. In multiple locations in the United States, a previously 
uncommon strain of C. difficile was found to be responsible for multiple, near-simultaneous 
outbreaks of hospital infection13,14.  It is characterized as North American Pulsed Field Type 1 
(NAP1), restriction enzyme analysis type “BI”, and PCR ribotype 02715.  The emergence of a 
previously uncommon strain of C. difficile that is more resistant and potentially more virulent 
than other strains indicates that inpatient health care facilities in North America need advances in 
available treatments, therapeutic management strategies, and diagnostics. 
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The presentation of CDAD is highly variable, ranging from symptomless carriage, to 
mild or moderate diarrhea with abdominal pain and cramps, to sudden and sometimes fatal 
pseudomembranous colitis7.  Clinical findings often include fever and lower abdominal 
tenderness with leukocytosis and hypoalbuminemia which can progress to toxic megacolon, a 
life-threatening widening or dilation of the large intestine, and septic shock16.   The typical 
clinical course is for resolution of symptoms within days of beginning antibiotic treatment.  
However, approximately 19-20% of affected patients will experience a symptomatic recurrence 
following their first episode of CDAD17.  This is typically defined for surveillance purposes as 
having a second positive test for C. difficile between two and eight weeks after successful 
therapy for the initial episode is completed18.   
The choice of initial antibiotic therapy for CDAD depends on the severity of disease.  
Metronidazole (500mg by mouth three times per day for 10-14 days) is the drug of choice for an 
initial episode of mild-to-moderate CDAD, while vancomycin (125mg by mouth four times per 
day for 10-14 days) is the drug of choice for an initial episode of severe CDAD.  A severe 
episode is defined as having leukocytosis with a white blood cell count of 15,000 cells/µL or 
higher and/or a serum creatinine level greater than or equal to 1.5 times the premorbid level12.  
Decreased response rates and slower responses for metronidazole compared to vancomycin have 
been noted since 200419,20,21.The antibiotic used to treat the initial infection is one of the few risk 
factors for recurrent CDAD that is modifiable, and these studies suggest that vancomycin may be 
the preferred drug of choice for treating an initial episode of CDAD in order to prevent 
recurrence. 
Some epidemiologic surveillance studies have suggested that 0.5%-1.5% of all 
hospitalized patients in the United States may develop CDAD22,23,24.  However, the number of 
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cases of both healthcare- and community-associated CDAD has increased dramatically in recent 
years25,26.One study has shown that the incidence rate of healthcare-associated CDAD has more 
than doubled in recent years, from 31 cases per 100,000 patients in 1996 to 84 cases per 100,000 
patients in 200527.  This increase in incidence is possibly due both to the overuse of certain 
antibiotics and the emergence of new virulent strains of the bacterium. 
 Risk factors for the initial symptomatic CDAD episode have been well documented and 
include advanced age (typically defined as over 65 years), prolonged duration of hospital stay, 
prolonged use of certain antibiotics, and the presence of underlying medical conditions such as 
inflammatory bowel disease (IBD), diabetes, immunodeficiency and HIV infection15.  However, 
epidemiologic risk factors for recurrent CDAD have not been described in as much detail.  A 
recent review found that important risk factors were similar to the established risk factors for the 
incident CDAD episode, including advanced age, long hospital stays, and continuation of 
antimicrobial therapy following the initial episode of CDAD28. A study examining data collected 
through surveillance by the Yale Emerging Infections Program (EIP) found older age, high white 
blood cell count prior to the first incident infection, use of H2 blockers (medicines that work by 
reducing the amount of stomach acid secreted by glands in the lining of your stomach), and 
previous antibiotic use to be risk factors for recurrence29.  
The previous Yale EIP study was based on data that did not include actual treatment 
given. Because recurrent CDAD is both common and costly, identifying modifiable risk factors 
is important. The objective of this study was to build on this previous work to further investigate 
risk factors for CDAD recurrence, especially with regards to the choice of antibiotic used to treat 
the initial infection.  
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Methods 
The Emerging Infections Programs (EIP) were established in 1995 in response to the Centers for 
Disease Control and Prevention’s (CDC) 1994 strategy, Addressing Emerging Infectious Disease 
Threats: A Prevention Strategy for the United States30.  The EIP is a network of 10 state health 
departments and their collaborators in local health departments, academic institutions, other 
federal agencies, and public health and clinical laboratories; hospital infection preventionists; 
and healthcare providers.  The EIP network is a national resource for surveillance, prevention, 
and control of emerging infectious diseases.  
C. difficile infection surveillance is being conducted in seven EIP sites throughout the 
United States. The surveillance system is designed to determine the population-based incidence 
of CDAD and describe the epidemiology of CDAD and generate hypotheses for future research 
activities using EIP CDAD surveillance infrastructure. The Connecticut EIP conducts active 
surveillance for CDAD through laboratory reporting in two population-based catchment areas: 
the New Haven and Waterbury, Connecticut metropolitan areas. This surveillance includes the 
collection of antibiotic history in the three months prior to the incident case of CDAD, but 
currently the CDC does not request the treatment information for this incident case.  The 
Connecticut EIP routinely receives lists of toxin-positive CDAD cases from all clinical 
laboratories and diagnostic laboratories throughout the New Haven and Waterbury areas.  These 
lists are evaluated to determine individual cases and classify the cases as either community onset 
(CO) cases that can be health care facility-associated (HCFA) or community associated (CA) or 
health care onset (HO, fig. 1).  Selected laboratories save stool samples on all cases of CDAD for 
further laboratory evaluation at the CDC including culture and toxinotype testing.  
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This was a pilot matched case-control study to look at differences in initial antibiotic 
treatment between CDAD patients reported to the Connecticut EIP who had a recurrent episode 
and those who only had a single episode (i.e. incident only). The study population was limited to 
persons reported from and treated at Yale-New Haven hospital during 2010-2011 inclusive 
because of feasibility related to data collection.  Recurrent cases eligible for this study were the 
81 persons > 1 year of age reported with C. difficile infections who had another positive C. 
difficile stool specimen between 2 to 8 weeks after the last positive specimen. Persons with only 
a single episode of CDAD were eligible to be controls and included patients with a C. 
difficile infection, defined as a positive C. difficile toxin assay or a positive C.difficile molecular 
assay (e.g., PCR), on a stool specimen who was 1 year of age or older, and who did not have a 
laboratory-documented recurrent episode.  Since age is one of the leading risk factors for CDAD, 
controls were matched to cases on this variable, within +/-two years of age at the time of incident 
infection.  Each case was matched with two controls whenever possible.  Chart reviews were 
done on all cases and controls, using Yale New Haven Hospital’s online medical records 
software, MDLink.  All HIPAA regulations were adhered to during the chart review process, and 
patient information was de-identified for analysis.  In this system, specific prescription orders 
were only available online for patients who were admitted to the hospital.   
Cases and controls were compared on categorical variables with the Fisher’s Exact Test 
or the chi-square test. Differences in continuous variables were analyzed with the Student’s t test.  
Stratified analyses were conducted by severity of incident infection and sex.  All statistical 
analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).   
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Results 
Of the 81 patients with a recurrent episode of C. difficile, 68 were included in this 
analysis.  Eight cases were excluded due to a lack of treatment information in the online medical 
records (e.g., outpatients, emergency room visits), and five due to a lack of age-matched 
controls.  At least one control, matched on age, was used for each case, and two were used 
wherever possible, resulting in a total study population of N=190.   
There were no significant differences between cases and controls for any of the general 
demographic and treatment variables studied, including ethnicity, number of underlying 
conditions, incident disease status, and treatment regimen used for the incident case (Table 1).  
There were several notable findings nonetheless. Females made up a greater proportion of cases 
than controls (67.7% of cases, 55.7% of controls, p=0.108).  Recurrent cases were nearly 70% 
less likely to have been treated initially with vancomycin than controls (7.4% vs 11.5%, OR: 
0.59; 95% CI: 0.20-1.26). In addition, recurrent cases who received vancomycin were 1.64 times 
more likely than controls not to have received a full standard course (29.2% vs 16.3%, OR: 1.64; 
95% CI: 0.57, 4.73).   
The data was stratified by the incident disease severity because there are different initial 
treatment recommendations depending on CDAD severity.  There were 22 severe cases and 40 
severe controls (Table 2).  None of the main demographic or treatment variables was statistically 
significant among severe cases, although sex was marginally significantly different (p=0.079) 
with recurrent cases being more likely than controls to be females (81.8% vs 60.0%).  Among all 
62 severe cases, only 5 (8.1%) were initially treated with vancomycin. Recurrent cases were less 
than half as likely as controls to be initially treated with vancomycin (OR: 0.44; 95% CI: 0.04-
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4.38).  They were also more likely when treated to have a less than full standard course of 
treatment (OR:3.00; 95% CI 0.46-19.49).  Sex did not appear to be a confounder among severe 
cases and controls, as the adjusted odds ratios for all the variables remained fairly consistent with 
the crude odds ratios. 
There were 41 cases and 77 controls with mild/moderate incident disease severity (Table 
3).  Similar to the severe cases, none of the main demographic variables had a statistically 
significant difference between the groups.  The number of underlying conditions was marginally 
significant (p=0.055);  a higher proportion of cases than controls had at least one underlying 
condition.  One notable treatment finding was that among those treated with metronidazole, 
recurrent cases were less likely (p=0.029) than controls to have received a less than standard 
course (i.e., more likely to have received a full course. OR: 0.32; 95% CI: 0.12, 0.85).  Sex did 
not appear to be a confounder among the mild/moderate cases and controls, as the adjusted odds 
ratios for all the variables remained consistent with the crude odds ratios.   
Because female sex was a predictor for recurrence in this study, stratified analyses by 
disease severity and sex variables were conducted.  For the severe patients, there were no 
significant differences with regards to demographic or outcome variables among males or 
females (Table 4) and there was little confounding of any of the treatment variables by sex (data 
not shown).  Among the mild/moderate patients, the finding that recurrent cases were more likely 
than controls to have had a full course of metronidazole was driven mainly by females (Table 5).  
A total of 90% of female recurrent patients treated with metronidazole had a full treatment 
course compared to 57.9% of controls (p=0.011). 
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Discussion 
 
 Recurrent Clostridium difficile infection is becoming more common in healthcare 
settings, and is quite costly.  This single institution pilot study aimed to identify modifiable risk 
factors, especially with regards to the treatment of the incident CDAD, and to inform whether 
treatment data should be collected for future CDAD surveillance.   
 There are several important findings of this study based on the magnitude of the point 
estimate for differences with respect to treatment of initial infection as a risk factor for recurrent 
CDAD infection, despite the lack of statistical significance of them. First, initial treatment with 
vancomycin appeared to substantially reduce risk of recurrence: recurrent cases were 70% less 
likely to have received vancomycin for the initial infection. Second, regardless of when it is used 
in the initial treatment of CDI, having anything less than 10-14 days of treatment with 
vancomycin, the recommended regimen, is associated with a higher risk of recurrence.  
Recurrent cases were nearly twice as likely to have less than 10 days of vancomycin.  Third, 
recurrent cases who initially had mild/moderate CDAD were more than twice as likely to have 
been treated with a full course of metronidazole.  
In a prospective, randomized, double-blind, placebo-controlled trial, it was shown that 
metronidazole and vancomycin were equally effective for the treatment of mild CDAD, but 
vancomycin was superior for treating patients with severe CDI31.  Our results suggest that 
vancomycin may be superior as the initial treatment, regardless of disease severity.  Prospective 
trials of metronidazole and vancomycin therapy have not looked at the risk of recurrence with 
regards to the duration of treatment25.  It is possible that a patient receiving a full course of 
metronidazole did not receive vancomycin, and thus would have greater odds of recurring.   
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An additional and somewhat surprising finding was that vancomycin was being underused for 
initial treatment of severe CDAD according to the clinical practice guidelines put forth by the 
Society for Healthcare Epidemiology of America.  The 2010 update stipulates that vancomycin is 
the recommended antibiotic for treating incident CDI deemed severe, which is defined as 
leukocytosis with a white blood cell count of 15,000 cells/µL or higher within one day before or 
after date of incident stool collection.  However, this study showed that a very small proportion 
of all severe cases received vancomycin as initial treatment (8.1%).  Many factors go into a 
doctor’s choice of antibiotic that could not be obtained from the online medical records, and such 
factors could shed additional light on treatment decisions.  However, based solely on the 
recommended treatment guidelines for CDAD, it appears that vancomycin is being underused for 
initial treatment of severe CDI.   
One possible reason for the lack of vancomycin use is cost.  The major advantage of 
metronidazole over vancomycin is its much lower price. Cost of a 10-day course of 
metronidazole is ∼$20, whereas the cost of a 10-day course of oral vancomycin (Vancocin) 
increased from $300 to $600 when the drug became more widely used in the United States. 
Some hospitals have avoided this issue by compounding the intravenous formulation into an oral 
formulation, thus reducing the price of a 10-day course to $45.32  However, this practice is not 
common.  Furthermore, it is also possible that the additional costs incurred by vancomycin 
therapy would be compensated by savings on the management of CDAD recurrence. As 
mentioned earlier, the cost per patient with CDI requiring admission to the intensive care unit 
$3006 per case to as high as $15,397.  A more formal study of the cost effectiveness of using 
metronidazole versus vancomycin is needed, especially taking into account recurrent disease and 
the costs associated with it. 
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 This pilot study brings to light information that should be addressed in the future, 
especially in routine surveillance.  Currently the CDC-funded EIP surveillance does not collect 
treatment information.  Additional collection of antibiotic treatment information on all incident 
cases of CDAD for routine surveillance could inform best practices.   
The results of this study are insufficient to make treatment recommendations, however in 
light of these findings Yale New Haven Hospital may want to revisit their practices for treating 
CDAD.  Examining the reasons of low use of vancomycin for severe CDAD goes beyond the 
scope of this study, and greater in-depth analysis of CDAD treatment would need to be 
conducted by the hospital epidemiologist, or someone on site, in order to truly understand the 
lack of vancomycin use.   
This study had additional limitations, including the small sample size.  This lack of 
statistical power made it difficult to observe any significant differences among the cases and 
controls, or risk factors for recurrence.  Increasing the duration of the study and/or the number of 
hospitals could increase statistical power and generalizability.  Other limitations include the fact 
that this was an observational study that did not permit full assessment of all potential 
confounders.  This study was also limited to inpatients, who could not be included due to a lack 
of information in their online medical records.  Results and conclusions are also based on what 
the patients were prescribed and information about whether patients completed their treatment 
regimens as ordered by the physician was not known.  
Despite the small sample size and lack of statistical power, our study suggests that 
vancomycin is the superior treatment for CDAD, yet it is being underused at Yale New Haven 
Hospital.  Persons started on vancomycin as compared to metronidazole have a lower risk of 
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recurrence, regardless of initial disease severity.  An initial treatment with vancomycin appeared 
to substantially reduce the risk of recurrence, yet only a small proportion of patients are receiving 
this antibiotic for reasons that remain unknown.  The results of this study have potential impacts 
on the future of surveillance and altering treatment regimens. Surveillance for recurrent CDAD 
should include information on treatment of the initial infection, and future studies should be 
conducted on the cost-benefit of using vancomycin instead of metronidazole for the initial 
treatment of CDAD, taking into account the potential for recurrence.   
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Tables and Figures 
 
Table 1.  Comparison of cases and controls by selected demographic and risk factors, Clostridium 
difficile-associated diarrhea (CDAD) patients, YNHH, 2010-11a 
 
Characteristic 
Recurrence, 
n=68 (%)b 
Incident only, 
n=122(%)b Odds Ratio pc 
Age at incident stool collection (years) 66.4+19.5 67.3+19.2  0.759 
Sex    0.108 
     Male 22 (32.4) 54 (44.3) ref  
     Female 46 (67.7) 68 (55.7) 1.66 (0.89, 3.09)  
Incident Disease Statusd    0.626 
     Mild/Moderate 41 (60.3) 77 (63.1) ref  
     Severe 22 (32.4) 40 (32.8) 1.03 (0.54, 1.97)  
Ethnicity    0.158 
     Non-Hispanic or Latino 64 (94.1) 107 (87.7) ref  
     Hispanic or Latino 4 (5.9) 15 (12.3) 0.45 (0.14, 1.40)  
Underlying conditions    0.649 
0 7 (10.3) 17 (13.9) ref  
>1 61 (89.7) 105 (86.1) 1.41 (0.55, 3.59)  
Treatment for Incident Case    0.632 
     Received Metronidazole IV/PO only 44 (64.7) 73 (59.8) ref  
     Received Vancomycin PO only 5 (7.4) 14 (11.5) 0.59 (0.20, 1.76)  
     Received Combination 19 (27.9) 35 (28.7) 0.90 (0.46, 1.76)  
Received Vancomycin?    0.508 
     Yes 24 (35.3) 49 (40.2) ref  
     No 44 (66.7) 73 (59.8) 1.23 (0.67, 2.28)  
Received Metronidazole?    0.952 
     Yes 60 (88.2) 108 (88.5) ref  
     No 8 (11.8) 14 (11.5) 1.03 (0.41, 2.59)  
Vancomycin duration    0.202 
     At least standard 17 (70.8)  41 (83.7) ref  
     Less than standard 7 (29.2) 8 (16.3) 2.11 (0.67, 6.74)  
Metronidazole duration    0.111 
     At least standard 45 (75.0) 68 (63.0) ref  
     Less than standard 15 (25.) 40 (37.0) 0.58 (0.29, 1.15)  
 
a
 Table values are mean ± SD for continuous variables and n (column %) for categorical variables. 
b
 Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding. 
 c
 P-value is for t-test (continuous variables) or χ² test or Fisher’s exact test (categorical variables). 
d
 Clinical definition (Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the 
Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America): 
 
Mild or moderate: Leukocytosis with a white blood cell count of less than 15,000 cells/µL within 1 day 
before or after date of incident stool collection 
 
Severe: Leukocytosis with a white blood cell count of 15,000 cells/µL or higher within 1 day before or 
after date of incident stool collection 
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Table 2.  
Comparison of severe cases and controls by selected demographic and risk factors, Clostridium difficile-
associated diarrhea (CDAD) patients, YNHH, 2010-11a 
 
 
Characteristic 
Recurrence, 
n=22 (%)b 
Incident only, 
n=40(%)b 
Crude Odds 
Ratio 
Adjusted Odds 
Ratioc pd 
Age at incident stool collection (years) 71.9+22.2 70.7+15.2   0.825 
Sex     0.079 
     Male 4 (18.2) 16 (40.0) ref   
     Female 18 (81.8) 24 (60.0) 
3.00 (0.86, 
10.52) 
 
 
Ethnicity     0.889 
     Non-Hispanic or Latino 20 (90.9) 36 (90.0) ref ref  
     Hispanic or Latino 2 (9.1) 4 (10.0) 0.90 (0.15, 5.35) 0.74 (0.12, 4.72)  
Underlying conditions     0.513 
0 5 (22.7) 5 (12.5) ref ref  
>1 17 (77.3) 35 (87.5) 0.49 (0.12, 1.91) 0.48 (0.12, 1.97)  
Treatment for Incident Case     0.850 
     Received Metronidazole IV/PO only 12 (54.6) 21 (52.5) ref ref  
     Received Vancomycin PO only 1 (4.6) 4 (10.0) 0.44 (0.04, 4.38) 0.76 (0.20, 2.97)  
     Received Combination 9 (40.9) 15 (37.5) 1.05 (0.35, 3.12) 1.24 (0.40, 3.84)  
Received Vancomycin?     0.823 
     Yes 10 (45.5) 19 (47.5) ref ref  
     No 12 (54.6) 21 (52.5) 1.09 (0.38, 3.08) 0.97 (0.33, 2.86)  
Received Metronidazole?     0.993 
     Yes 21 (95.5) 36 (90.0) ref ref  
     No 1 (4.6) 4 (10.0) 0.43 (0.05, 4.09) 0.83 (0.25, 2.80)  
Vancomycin duration     0.775 
     At least standard 7 (70.0) 17 (89.5) ref ref  
     Less than standard 3 (30.0) 2 (10.5) 
3.00 (0.46, 
19.49) 
2.40 (0.29, 
19.80)  
Metronidazole duration     0.900 
     At least standard 13 (61.9) 23 (63.9) ref ref  
     Less than standard 8 (38.1) 13 (36.1) 1.19 (0.40, 3.54) 1.29 (0.41, 4.10)  
 
 
a
 Table values are mean ± SD for continuous variables and n (column %) for categorical variables. 
b
 Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding. 
c Adjusted for sex 
d
 P-value is for t-test (continuous variables) or χ² test or Fisher’s exact test (categorical variables).  The corrected 
Mantel-Haenszel p-value is used for variables where a sex-adjusted Odds Ratio was calculated. 
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Table 3.  
Comparison of mild/moderate cases and controls by selected demographic and risk factors, Clostridium 
difficile-associated diarrhea (CDAD) patients, YNHH, 2010-11a 
 
 
Characteristic 
Recurrence, 
n=41 (%)b 
Incident only, 
n=77(%)b Crude Odds Ratio 
Adjusted Odds 
Ratioc pd 
Age at incident stool collection (years) 63.9+18.3 66.9+19.8   0.426 
Sex     0.443 
     Male 16 (39.0) 36 (46.8) ref   
     Female 25 (61.0) 41 (53.3) 1.37 (0.64, 2.97)   
Ethnicity     0.283 
     Non-Hispanic or Latino 39 (95.1) 67 (87.0) ref ref  
     Hispanic or Latino 2 (4.9) 10 (13.0) 0.34 (0.07, 1.65) 0.34 (0.07, 1.64)  
Underlying conditions     0.108 
0 1 (2.4) 11 (14.3) ref ref  
>1 40 (97.6) 66 (85.7) 
6.67 (0.83, 53.60) 6.34 (0.78, 
51.80)  
Treatment for Incident Case     0.815 
     Received Metronidazole IV/PO only 29 (70.7) 50 (64.9) ref ref  
     Received Vancomycin PO only 3 (7.3) 7 (9.1) 0.74 (0.18, 3.08) 0.76 (0.18, 3.24)  
     Received Combination 9 (22.0) 20 (26.0) 0.78 (0.31, 1.93) 0.77 (0.32, 1.88)  
Received Vancomycin?     0.643 
     Yes 12 (29.3) 27 (35.1) ref ref  
     No 29 (70.7) 50 (64.9) 1.31 (0.58, 2.96) 1.32 (0.59, 2.96)  
Received Metronidazole?     0.432 
     Yes 35 (85.4) 71 (92.2) ref ref  
     No 6 (14.6) 6 (7.8) 2.03 (0.61, 6.75) 1.98 (0.59, 6.65)  
Vancomycin duration     0.687 
     At least standard 8 (66.7) 21 (77.8) ref ref  
     Less than standard 4 (33.3) 6 (22.2) 1.28 (0.34, 4.82) 1.86 (0.40, 8.68)  
Metronidazole duration     0.052 
     At least standard 29 (82.9) 44 (62.0) ref ref  
     Less than standard 6 (17.1) 27 (38.0) 0.32 (0.12, 0.85) 0.35 (0.13, 0.93)  
 
a
 Table values are mean ± SD for continuous variables and n (column %) for categorical variables. 
b
 Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding.   
c Adjusted for sex 
d
 P-value is for t-test (continuous variables) or χ² test or Fisher’s exact test (categorical variables).  The corrected 
Mantel-Haenszel p-value is used for variables where a sex-adjusted Odds Ratio was calculated. 
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Table 4.  
Comparison of severe cases and controls, stratified by recurrence status and sex, Clostridium difficile-associated diarrhea (CDAD) patients, 
YNHH, 2010-11a 
 
 Males, n=20 Females, n=42 
Characteristic 
Recurrence, 
n=4 (%)b 
Incident only, 
n=16 OR p 
Recurrence, 
n=18 (%)b 
Incident only, 
n=24 OR pc 
Age at incident stool collection (years) 71.0+23.8 67.69+15.99  0.740 72.11+22.56 72.8+14.6  0.912 
Ethnicity    1.000    1.000 
     Non-Hispanic or Latino 4 (100.0) 15 (93.8) ref  16 (88.9) 21 (87.5) ref  
     Hispanic or Latino 0 1 (6.25) <0.  2 (11.1) 3 (12.5) 0.88 (0.13, 5.87)  
Underlying conditions    0.509    0.438 
0 1 (25.0) 2 (12.5) ref  4 (22.2) 3 (12.5) ref  
>1 3 (75.0) 14 (87.5) 0.43 (0.03, 6.41)  14 (77.8) 21 (87.5) 0.50 (1.00, 2.58)  
Treatment for Incident Case    1.000    0.731 
     Received Metronidazole IV/PO only 2 (50.0) 7 (43.8) ref  10 (55.6) 14 (58.3) ref  
     Received Vancomycin PO only 0 1 (6.3) <0.01   1 (5.6) 3 (12.5) 0.47 (0.04, 5.17)  
     Received Combination 2 (50.0) 8 (50.0) 0.88 (1.00, 7.95)  7 (38.9) 7 (29.2) 1.40 (0.37, 5.27)  
Received Vancomycin?    1.000    1.000 
     Yes 2 (50.0) 9 (56.3) ref  8 (44.4) 10 (41.2) ref  
     No 2 (50.0) 7 (43.8) 1.29 (0.14, 11.54)  10 (55.6) 14 (58.3) 0.89 (0.26, 3.07)  
Received Metronidazole?    1.000    0.623 
     Yes 4 (100.0) 15 (93.8) ref  17 (94.4) 21 (87.5) ref  
     No 0 1 (6.3) <0.01   1 (5.6) 3 (12.5) 0.41 (0.04, 4.33)  
Vancomycin duration    1.000    0.608 
     At least standard 2 (100.0) 9 (100.0) ref  5 (62.5) 8 (80.0) ref  
     Less than standard 0  0  N/A  3 (37.5) 2 (20.0) 2.20 (0.33, 14.79)  
Metronidazole duration    0.303    1.000 
     At least standard 1 (25.0) 9 (60.0) ref  12 (70.6) 14 (66.7) ref  
     Less than standard 3 (75.0) 6 (40.0) 5.00 (0.42, 59.64)  5 (29.4) 7 (33.3) 0.93 (0.24, 3.63)  
 
a
 Table values are mean ± SD for continuous variables and n (column %) for categorical variables. 
b
 Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding. 
 c
 P-value is for t-test (continuous variables) or χ² test or Fisher’s exact test (categorical variables). 
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Table 5.  
Comparison of mild/moderate cases and controls, stratified by recurrence status and sex, Clostridium difficile-associated diarrhea (CDAD) 
patients, YNHH, 2010-11a 
 
 
 
Males, n=52 Females, n=66 
Characteristic 
Recurrence, 
n=16 (%)b 
Incident only, 
n=36 OR p 
Recurrence, 
n=25 (%)b 
Incident only, 
n=41 OR pc 
Age at incident stool collection (years) 62.1+21.1 64.7+19.8   0.670 65.0+16.6 68.7+19.9  0.415 
Ethnicity    1.000    0.239 
     Non-Hispanic or Latino 15 (93.8) 32 (88.9) ref  24 (96.0) 35 (85.4) ref  
     Hispanic or Latino 1 (6.3) 4 (11.1) 0.53 (0.06, 5.19)  1 (4.0) 6 (14.6) 0.24 (0.03, 2.15)  
Underlying conditions    0.409    0.289 
0 1 (6.3) 7 (19.4)  ref  0 4 (9.8) ref  
>1 15 (93.8) 29 (80.6) 3.62 (0.41, 32.21)  25 (100.0) 37 (90.2) >999.99   
Treatment for Incident Case    0.500    0.295 
     Received Metronidazole IV/PO only 10 (62.5) 26 (72.2) ref  19 (76.0) 24 (58.5) ref  
     Received Vancomycin PO only 1 (6.3) 4 (11.1) 0.65 (0.07, 6.55)  2 (8.0) 3 (7.3) 0.84 (0.13, 5.56)  
     Received Combination 5 (31.3) 6 (16.7) 2.17 (0.54, 8.73)  4 (16.0) 14 (34.2) 0.36 (0.10, 1.28)  
Received Vancomycin?    0.527    0.188 
     Yes 6 (37.5) 10 (27.8) ref  6 (24.0) 17 (41.5) ref  
     No 10 (62.5) 26 (72.2) 0.64 (0.18, 2.23)  19 (76.0) 24 (58.5) 2.24 (0.74, 6.80)  
Received Metronidazole?    1.000    0.242 
     Yes 15 (93.8) 33 (91.7) ref  20 (80.0) 38 (92.7) ref  
     No 1 (6.3) 3 (8.3) 0.73 (0.07, 7.64)  5 (20.0) 3 (7.3) 3.17 (0.69, 14.63)  
Vancomycin Duration    0.125    1.000 
     At least standard 4 (66.7) 10 (100.0) ref  4 (66.7) 11 (64.7) ref  
     Less than standard 2 (33.3) 0 >999.99   2 (33.3) 7 (35.3) 0.51 (0.09, 2.73)  
Metronidazole Duration    0.746    0.012 
     At least standard 11 (73.3) 22 (66.7) ref  18 (90.0) 22 (57.9) ref  
     Less than standard  4 (26.7) 11 (33.3) 0.76 (0.20, 2.88)  2 (10.0) 16 (42.1) 0.14 (0.03, 0.66)  
 
a
 Table values are mean ± SD for continuous variables and n (column %) for categorical variables. 
b
 Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding. 
 c
 P-value is for t-test (continuous variables) or χ² test or Fisher’s exact test (categorical variables). 
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Figure 1.Time line for definitions of Clostridium difficile–associated disease (CDAD) exposures. Case 
patients with symptom onset during the window of hospitalization marked by an asterisk (∗) would be classified as 
having community-onset, healthcare facility–associated disease (CO-HCFA), if patient was discharged from a 
healthcare facility within the previous 4 weeks; would be classified as having indeterminate disease, if the patient 
was discharged from a healthcare facility between the previous 4-12 weeks; or would be classified as having 
community-associated CDAD (CA-CDAD), if the patient was not discharged from a healthcare facility in the 
previous 12 weeks. HO-HCFA, healthcare facility–onset, healthcare facility–associated CDAD. 33 
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